Standard-of-care first-line treatment for metastatic urothelial carcinoma (mUC) is platinum-
based chemotherapy (CTx). Maintenance immunotherapy is a treatment option for patients …

Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma …

Background Patients with metastatic urothelial carcinoma (mUC) who progress after
platinum-based chemotherapy have had few treatment options and uniformly poor …

Atezolizumab is an anti–PD-L1 immune checkpoint inhibitor recommended for the treatment
of locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing …

Background IMvigor130 demonstrated statistically significant investigator-assessed
progression-free survival benefit with first-line atezolizumab plus platinum-based …

Background Clinical trials of atezolizumab for locally advanced or metastatic urothelial
bladder cancer (mUBC) report controversial efficacy data. Furthermore, real-world evidence …

Background Despite initial promising results, the IMvigor211 clinical trial failed to
demonstrate an overall survival (os) benefit for atezolizumab compared with chemotherapy …

Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival …

Abstract Purpose Immune checkpoint inhibitors (ICIs) have been incorporated in the
treatment of metastatic urothelial carcinoma (mUC) upon platinum-based chemotherapy …

Purpose: The MORPHEUS platform was designed to identify early efficacy signals and
evaluate the safety of novel immunotherapy combinations across cancer types. The phase …